AstraZeneca’s Imfinzi Gains NMPA Approval for First-Line Cholangiocarcinoma Treatment
The National Medical Products Administration (NMPA) of China has indicated on its website that it...
NASDAQ: AZN
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
Among the series of deals secured by multinational corporations at the 6th China International Import...
AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third...
Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004
Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant...
AstraZeneca Expands China Presence with Over 30 Agreements at CIIE
At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc...
FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results
US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...
Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China
China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...
AstraZeneca Announces Positive Phase IIb Results for CKD Treatment Combination
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced last week that its combination therapy of...
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...
AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design...
EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC
The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu...
AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...
Ascentage Pharma and AstraZeneca Expand Collaboration on CLL/SLL Treatment
China’s Ascentage Pharma (HKG: 6855) and UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) have entered...
AstraZeneca Seeks Approval for Capivasertib in Combination with Faslodex for Breast Cancer Treatment
AstraZeneca (AZ, NASDAQ: AZN) has submitted a market approval filing for its Category 1 drug...
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical...
AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit
Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...
AstraZeneca Reports Positive Phase III Results for Forxiga in Children with Type 2 Diabetes
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced promising results from the Phase III T2NOW study...
EMA’s CHMP Backs Enhertu for Advanced NSCLC with HER2 Mutations
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC
UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...
AstraZeneca’s Fasenra Shows Non-Inferior Efficacy to Nucala in EGPA: Phase III Results
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has unveiled the results of a Phase III...